The EliSpot (Enzyme-linked Immunosorbent Spot Assay) measures the number of activated T-lymphocytes in cell cultures that release cytokines after being challenged by the relevant antigen.
The EliSpot (Interferon γ-test) is a test to detect an infection with Borrelia and various co-pathogens on a cellular level. The first generation of the enzymatic EliSpot provided key additional information on the status of the infection, together with the determination of the CD3 / CD57-NK cells.
This test has now been enhanced and the new EliSpot, ‘LymeSpot Revised’, provides even more detailed information on the activity of the infection. This test can help to identify whether an active (specific effector cells) or a latent (specific memory cells) phase of the infection is present. Thanks to this progress, we are in a much better position to assess inflammation and autoimmune processes.
While the existing Elispot test is exclusively based on the production of γ-Interferon, the new LymeSpot also determines Cytokine IL-2 production. In accordance with the traffic light principle, an active infection (predominantly effector cells) shows green in the test result, meaning that treatment of the infection is necessary. If the ratio of γ-Interferon and Interleukin-2 is reversed, a latent disease can be assumed, manifesting itself as the colour red in the laboratory test (predominantly memory cells). In this case, a mandatory anti-infective treatment would no longer be needed.
Material: 2 x 8.5 ml CPDA tubes (Do not centrifuge. Store at room temperature. Do not cool)
Turnaround time: Two days (Note: Taking into account the required pre- and post-analytical work, the report is created in about one week)
Further reading and studies can be found here.